key: cord-0877831-b2weyjp8
authors: Punzo, Ornella; Bellino, Stefania; Palmieri, Luigi; Lo Noce, Cinzia; Giuliano, Marina; Meli, Paola; Boros, Stefano; Bella, Antonino; Riccardo, Flavia; Pezzotti, Patrizio; Onder, Graziano
title: Clinical characteristics of individuals under 40 years of age who died with COVID‐19 in Italy
date: 2021-01-22
journal: J Med Virol
DOI: 10.1002/jmv.26788
sha: 0de64a8c4c81c84499ba502454eb3296f3810484
doc_id: 877831
cord_uid: b2weyjp8

nan

DOI: 10.1002/jmv.26788

To the Editor, Italy had a high death toll due to COVID-19 with 35,700 deaths and a case fatality rate (CFR) of 12% by September 21, 2020. Only 87 deaths were recorded in the age-group under 40 years old. We analyzed the clinical characteristics, comorbidities, and complications in this population, based on data coming from the epidemiological surveillance and 39 medical records.

The study population included COVID-19-related deaths <40 years, defined as those occurring in patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through Reverse Transcription Polymerase Chain Reaction, independently from pre-existing diseases that may have caused or contributed to death. [1] [2] [3] The primary outcome of the study was to examine the clinical characteristics of young adults who died with COVID-19, including details of hospital admission, disease symptoms, pre-existing medical conditions, pharmacological treatments, and complications that occurred during hospitalization. All deaths occurring in patients with confirmed COVID-19 were tracked by the Italian case-based surveillance system coordinated by the National Institute of Health (Istituto Superiore di Sanità [ISS]). We analyzed the data of confirmed SARS-CoV-2 deaths from February 20 until September 21, 2020, collected from all 21 regions and autonomous provinces. 4, 5 Additional data were obtained in a subset of hospitalized patients from medical records, as Regions were asked to send them to ISS. We included all medical records received to date, and as we had no control over this process, the sample was ultimately randomly collected and therefore representative. These clinical charts were reviewed by a group of researchers at ISS to obtain more detailed information on demographics, COVID-19-related symptoms, pre-existing comorbidities, pharmacological treatments, and complications leading to death. 6 The study was a part of public health and surveillance activities for the COVID-19 pandemic. On February 27, 2020, the Italian Presidency of the Council of Ministers authorized the collection and scientific dissemination of data related to COVID-19 by ISS. 7

In Italy, the total number of COVID-19 confirmed cases from the epidemiological surveillance by September 21, 2020 was 296,539, while the total number of deaths was 35,700, with a case fatality rate (CFR) of 12%. The number of COVID-19 cases among subjects under 40 was 69,854 with 87 deaths (CFR: 0.1%). The majority of these deaths involved males (65.5%) and the median age was 35 (Table 1) ; 78.2% were hospitalized (median length of stay: 15 days); 50% were admitted to the intensive care unit (ICU). The majority had more than one medical condition (35.6%), 34.5% had only one, and 29.9% had no pre-existing disease. The most common comorbidities were neurological or psychiatric disorders (45.9%), followed by cardiovascular diseases (31.1%), active cancer (27.9%), obesity, or other metabolic disorders including diabetes (21.7% each).

Of the 87 deaths, we retrieved medical records of 39 hospitalized patients (45%). The median age was 34 and the majority were males (61.5%) ( Table 1 ). The most common symptoms on hospital admission were fever (69.2%), dyspnoea (53.8%), and cough (46.1%). Radiological evidence of pneumonia was found in 74.4% of the patients. 56.4% of the patients were admitted to ICU and 87.2% underwent respiratory assistance. 48.7% of the deaths occurred in patients with more than one pre-existing disease, the most common of which were neurological or psychiatric conditions (48.4%), cardiovascular diseases (35.5%), active cancer (29%), obesity (25.8%). Among the nine cases of active malignancy, the most represented was breast cancer (three cases). Moreover, 10 patients had pre-existing disabilities, including some living in a long-term care facility. Four children (age ≤ 6 years) who died with SARS-CoV-2 were all suffering either from rare genetic diseases or cancer. Overall, 84.6% of patients were treated with antibiotics, 74.4% with antivirals or hydroxychloroquine, 56.4% with steroids, and almost 17.9% with tocilizumab. The most frequent complications recorded during the hospitalization were acute respiratory distress syndrome (84.6%), shock (41.5%), superinfection (33.3%), acute renal failure (20.5%), acute cardiac injury (12.8%).

It is worth acknowledging that recent estimates from the Italian serosurvey show that 1,482,000 people were infected by SARS-CoV-2, five times more than the number of cases recorded by ISS, lowering the CFR to 2.4%. 8 Moreover, in Italy, COVID-19 had no impact on excess mortality in the population under the age of 50, even in the most affected areas, with only 1% of the deaths involving this age-group. 9 As highlighted in a previous Italian study, the characteristics of younger patients who died with COVID-19 were different from the ones observed in the elderly. 6 Several studies showed similar findings compared with ours. In a large British study 12 15 This study also confirms that blood group 0 is associated with a lower risk of acquiring COVID-19, whereas blood group A was associated with a higher risk than non-A blood groups.

In our view, it is also crucial to reflect on the high proportion (26%) of patients in our sample with either physical or mental disability or suffering from a rare disease, that is, Marfan and Williams syndromes, rare cancers, congenital heart diseases, for whom taking precautions and using personal protective equipment may be difficult. We should protect these vulnerable patients through the implementation of infection control measures to prevent COVID-19 spread in long-term care facilities or hospitals.

This study has some limitations; first, the generalizability of our findings may be limited by the small sample size, however, the analysis covers more than 40% of all deaths in patients younger than 40 years in the country to date; moreover, our analysis is focused on patients dying in the hospital only, however, the patients in our sample were all hospitalized.

Overall, our data indicate that a low number of young persons die with COVID-19. Although the majority of the patients aged below 40 who died with COVID-19 suffered from previous and often severe Abbreviations: IQR, interquartile range; n.a., not available.

pre-existing conditions, a small proportion did not suffer from any

European Centre for Disease Prevention and Control. Case definition and European surveillance for COVID-19

Italian Ministry of Health. Ministerial Decree N. 0007922, 09/03/2020 -COVID-19. Aggiornamento della definizione di caso

Italian Ministry of Health. Ministerial Decree N. 11715, 03/04/2020-COVID-19. Aggiornamento della definizione di caso

Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic

COVID-19 disease severity risk factors for pediatric patients in Italy

Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy

Ordinanza 640 del 27.02.: Gazzetta Ufficiale n. 50; 2020

Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2

Impatto dell'epidemia COVID-19 sulla mortalità totale della popolazione residente periodo gennaio-maggio

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Impatto dell'epidemia covid-19 sulla mortalità: cause di morte nei deceduti positivi a SARS-CoV-2

OpenSAFELY: factors associated with COVID-19 death in 17 million patients

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

Genomewide association study of severe Covid-19 with respiratory failure

The authors declare that there are no conflict of interests. 

The data that supports the findings of this study are available in the supplementary (